TEL : 0091- 217 - 2310824
: 0091- 217 - 2451500
FAX : 0091- 217 - 2451521
E-MAIL : info@balajiamines.com
WEBSITE : http://www.balajiamines.com

ISO 45001:2018
ISO 14001:2015
ISO 9001:2015
TÜV Rheinland CERTIFIED
www.tuv.com
ID 9105038797
CIN : L24132MH1988PLC049387

AMINES LIMITED
... A Speciality Chemical Company

Regd. Off. : 'Balaji Towers' No. 9/1A /1,
Hotgi Road, Aasara Chowk, Solapur - 413 224.
Maharashtra. (India)

04th November, 2026

To,
The General Manager-Department of
Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

The Manager-Listing Department,
National Stock Exchange of India Limited,
"Exchange Plaza", 5th Floor, Plot No.C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051.

Scrip Code : 530999

Symbol : BALAMINES

Dear Sir/Madam,

Sub.: Investor Presentation on Q2 FY27 Financial Results

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation on Q2 FY27 Financial Results.

This Investor Presentation may also be accessed on the website of the Company at https://www.balajiamines.com/investor-relations.php.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For Balaji Amines Limited
ABHIJEET SHAILESH KOTHADIYA
Digitally signed by ABHIJEET SHAILESH KOTHADIYA
Date: 2026.11.04 12:18:41 +05'30'
Abhijeet Kothadiya
Company Secretary & Compliance Officer

Encl.: a/a


Balaji
AMINES LIMITED
...A Specialty Chemical Company
INDIA FIRST.
Building What India Needs Before India Asks for It.
BALAJI AMINES LIMITED
Investor Presentation | Q2 & H1 FY27

Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Balaji Amines Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Balaji AMINES LIMITED
...A Speciality Chemical Company

FINANCIAL HIGHLIGHTS Q2 & H1 FY27



Key Highlights of the Quarter



Mr. Dundurapu Ram Reddy
Managing Director

Q2 FY27 reflected resilient execution and steady progress on our strategic priorities. On a consolidated basis, Total Revenue grew 36% year-on-year to ₹472 crore, EBITDA rose 58% to ₹106 crore with a margin of 22%, and PAT increased 82% to ₹67 crore. For H1 FY27, consolidated PAT nearly doubled to ₹146 crore.

Volumes were dented by external factors, including raw material availability and delayed supply chains, yet our stable product portfolio kept the top line resilient, with standalone volumes improving 11% over Q1. Commercial production commenced at our upgraded Acetonitrile facility, and with PESO approval of DME road tanker valves, we are now building our DME customer network.


N-Methyl Morpholine is our next product for commercialisation, while BSCL's Unit-I brownfield expansion is on track for commissioning by end-FY27 and the Unit-II HCN, NaCN and EDTA project is targeted for Q4 FY27. With a visible expansion roadmap and disciplined execution, we remain confident of driving sustainable growth and long-term shareholder value.




Financial highlights – Q2 FY27

STANDALONE


Total Revenue (INR Cr)




EBITDA (INR Cr)



PAT (INR Cr)




EBITDA & PAT MARGIN (%)




CONSOLIDATED


Total Revenue (INR Cr)




EBITDA (INR Cr)



PAT (INR Cr)




EBITDA & PAT MARGIN (%)



Financial highlights – H1 FY27

STANDALONE

Total Revenue (INR Cr)




EBITDA (INR Cr)



PAT (INR Cr)




EBITDA & PAT MARGIN (%)




CONSOLIDATED


Total Revenue (INR Cr)




EBITDA (INR Cr)



PAT (INR Cr)



EBITDA & PAT MARGIN (%)



Standalone Statement of Profit & Loss

Particulars (Rs.Crs.)	Q2FY27	Q2FY26	Y-o-Y	Q1FY27	Q-o-Q	H1 FY27	H1 FY26
Total Revenue	**434**	**316**	**37.33%**	**429**	**1.24%**	**863**	**643**
Total Raw Material	239	177		237		476	357
Employee Expenses	24	18		24		48	37
Other Expenses	68	65		58		126	128
EBITDA	**103**	**57**	**81.39%**	**110**	**-5.71%**	**213**	**121**
EBITDA Margin (%)	**24%**	**18%**		**26%**		**25%**	**19%**
Depreciation	13	12		12		24	23
EBIT	**91**	**45**	**99.40%**	**98**	**-7.58%**	**189**	**98**
EBIT Margin (%)	**21%**	**14%**		**23%**		**22%**	**15%**
Finance Cost	0	0		0		0	1
Profit before Tax	**90**	**45**	**100.83%**	**98**	**-7.55%**	**188**	**97**
Profit before Tax(%)	**21%**	**14%**		**23%**		**22%**	**15%**
Tax	22	14		26		47	26
Profit After Tax	**69**	**31**	**118.55%**	**72**	**-4.73%**	**141**	**71**
PAT Margin (%)	**16%**	**10%**		**17%**		**16%**	**11%**
EPS (As per Profit after Tax)	21.21	9.71		22.27		43.48	21.99

Consolidated Statement of Profit & Loss

Particulars (Rs.Crs.)	Q2FY27	Q2FY26	Y-o-Y	Q1FY27	Q-o-Q	H1 FY27	H1 FY26
Total Revenue	**472**	**348**	**35.78%**	**461**	**2.28%**	**933**	**715**
Total Raw Material	265	185		253		518	397
Employee Expenses	26	19		26		52	40
Other Expenses	75	76		61		136	147
EBITDA	**106**	**67**	**58.46%**	**121**	**-12.72%**	**227**	**131**
EBITDA Margin (%)	**22%**	**19%**		**26%**		**24%**	**18%**
Depreciation	15	14		14		29	28
EBIT	**91**	**53**	**72.36%**	**108**	**-15.77%**	**198**	**102**
EBIT Margin (%)	**19%**	**15%**		**23%**		**21%**	**14%**
Finance Cost	1	1		1		3	2
Profit before Tax	**89**	**52**	**72.96%**	**106**	**-15.92%**	**196**	**101**
Profit before Tax(%)	**19%**	**15%**		**23%**		**21%**	**14%**
Tax	22	15		28		50	27
Profit After Tax	**67**	**37**	**81.85%**	**78**	**-13.63%**	**146**	**74**
PAT Margin (%)	**14%**	**11%**		**17%**		**16%**	**10%**
EPS (As per Profit after Tax)	20.76	10.67		23.13		43.89	22.39

Consolidated Balance Sheet Statement

ASSETS (Rs. Crs.)	Sep-26	Mar-26
(1) NON-CURRENT ASSETS		
(a) Property, plant & equipment	1,160	1,035
(b) Capital work-in-progress	513	512
(c) Other Intangible assets	3	3
(d) Intangible asset under development	0	0
(e) Investment Property	4	5
(f) Right-of-use assets	0	0
(g) Financial Assets		
(i) Investments	0	0
(ii) Other Financial Assets	12	15
(h) Other Non - current assets	31	232
Sub Total (A)	**1,723**	**1,802**
(2) CURRENT ASSETS		
(a) Inventories	282	247
(b) Financial Assets		
(i) Trade receivables	389	346
(ii) Cash and cash equivalents	53	74
(iii) Bank Balances other than (iii) above	175	197
(iv) Other (to be specified)	0	0
(c) Current tax assets (net)	0	0
(d) Other current assets	109	76
Sub Total (B)	**1,008**	**941**
Total Assets (A+B)	**2,731**	**2,743**

EQUITY AND LIABILITIES (Rs. Crs.)	Sep-26	Mar-26
EQUITY		
(a) Equity Share capital	6	6
(b) Other equity	2,077	1,970
Attributable to owner of parent	2,083	1,976
Non controlling interest	179	175
Sub Total (C)	**2,262**	**2,152**
LIABILITIES		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Lease Liabilities	0	0
(ii) Borrowings	129	65
(iii) Other Financial Liabilities	5	5
(b) Provisions	3	3
(c) Deferred Tax Liabilities (Net)	122	114
(d) Other Non-Current Liabilities	1	1
Sub Total (D)	**261**	**189**
(2) Current Liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	0	0
(ii) Borrowings	32	68
(iii) Trade Payables	70	85
(iv) Other Financial Liabilities	81	222
(b) Other current liabilities	10	15
(c) Provisions	2	1
(d) Current tax liabilities (Net)	14	11
Sub Total (E)	**208**	**402**
Total Equity & Liabilities (C+D+E)	**2,731**	**2,743**

Consolidated Cash Flow Statement

Cash Flow Statement for half year ended (in Rs. Crore)	Sep-26	Sep-25
Profit before Tax	196	101
Adjustment for Non-Operating Items	28	22
Operating Profit before Working Capital Changes	**224**	**122**
Changes in Working Capital	-143	-85
Cash Generated from Operations	**80**	**38**
Less: Direct Taxes paid	-26	-16
Net Cash from Operating Activities	**54**	**22**
Cash Flow from Investing Activities	**-67**	**-115**
Cash Flow from Financing Activities	**-9**	**-17**
Net increase/ (decrease) in Cash & Cash equivalent	**-21**	**-110**
Add: Cash and cash equivalents	**74**	**149**
Cash and cash equivalents as at 30th September, 2026	**53**	**39**

Balaji AMINES LIMITED
...A Speciality Chemical Company


COMPANY OVERVIEW



At a Glance

WE BUILT INDIA's 1st INDIGENOUS TECHNOLOGY FOR MANUFACTURING ALIPHATIC AMINES

Driven by innovation and import substitution, Balaji Amines continues to strengthen its specialty chemicals portfolio through differentiated products and disciplined expansion.



Corporate Structure

4 Manufacturing Locations

Strong multi-location manufacturing base

2 Speciality Chemical Units (BSCL)

Focus on High- Value Speciality Chemicals

Operations across **Maharashtra & Telangana**

Strategically located for scale and efficiency

Balaji Amines Ltd

BALAJI AMINES

(Core Manufacturing)

Leading manufacturer of aliphatic amines and speciality chemicals

- **Unit I** — Solapur
- **Unit II** — Telangana
- **Unit III** — Solapur
- **Unit IV** — Solapur

BALAJI SPECIALITY CHEMICALS LTD (Subsidiary)

Expanding the portfolio of speciality for high-growth industries

- **BSCL Unit I** — Solapur
- **BSCL Unit II** — Solapur

Hotel Balaji Sarovar

Hospitality Division

Manufacturing Locations – Built for Scale

BALAJI AMINES

Unit I – Solapur

Key Products:

- Methylamines
- Ethyl amines
- Morpholine
- Isopropyl amines (MIPA)
- Dimethylamine (DMA)
- Dimethyl Acetamide
- Dimethyl Urea
- Choline Chloride and other derivatives
- Dimethyl Amino Ethanol (DMAE)
- Diethyl Amino Ethanol (DEAE)

Unit II – Telangana

Key Products:

- Dimethylamine (DMA)
- Hydrochloride (HCl)

Unit III – Solapur

Key Products:

- Dimethyl Formamide
- Morpholine
- Acetonitrile
- Polyvinylpyrrolidone
- Methylamines
- Dimethyl Amine Hydrochloride
- Gamma-Butyrolactone
- N-Methyl Pyrrolidone
- 2-Pyrrolidone

Unit IV – Solapur

Key Products:

- Ethyl amines
- Methylamines
- N-Butylamine
- Dimethyl Carbonate (DMC)
- Propylene Carbonate (PC)
- Propylene Glycol (PG)
- Dimethyl Ether (DME)
- N-Methyl Morpholine (NMM)

Certifications:

- **ISO 9001:2015** Quality Management Systems
- **ISO 14001:2015** Environmental Management
- **ISO 45001:2018** Occupational Health & Safety
- **WHO-GMP** Required for pharma-linked regulated markets
- **Three- Star Export House**
- **REACH**
- **FAMI-QS**

BALAJI SPECIALITY CHEMICALS LTD (BSCL)

BSCL Unit I

Key Products Include:

- EDA
- DETA
- TETA
- Piperazine
- AEEA
- AEP

BSCL Unit II

Key Products Include:

- HCN
- Sodium Cyanide
- EDTA
- EDTA – 2Na
- Cyanation R&D plant

Certifications:

- **ISO ISO 9001:2015**
- **ISO 14001:2015**
- **ISO 45001:2018**
- **REACH –EDA & DETA**
- **Two-Star Export House**

Executing the Next Growth Phase

Commissioning key projects while advancing the next phase of speciality chemicals expansion.



DME Successfully Commissioned (Q1 FY27)

STATUS: OPERATIONAL

- 100,000 TPA DME plant commissioned in Q1 FY27, marking India's first commercial-scale DME manufacturing facility.
- Creates exposure to clean fuel, LPG blending and Aerosol as a propellant application in healthcare and personal care sectors, strengthening the Company's wide product portfolio.



ACN Commercialized | NMM Under Execution

STATUS: ACN (OPERATIONAL)
NMM (UNDER EXECUTION)

- **Acetonitrile (ACN):** Commercial production commenced at the expanded Unit III facility, incorporating an improved manufacturing process to strengthen cost competitiveness.
- **N-Methyl Morpholine (NMM):** The 5,000 TPA project is progressing, with commissioning expected during FY27, further broadening the Company's specialty chemicals portfolio.



R&D Mechanism

IN-HOUSE R&D PROGRAMME

- Higher utilization of recently commissioned capacities expected to improve operational efficiency.
- Ongoing capacity additions continue to strengthen the Company's speciality chemicals platform.

As new capacities come on stream and ongoing projects progress toward commissioning, Balaji Amines is well positioned to leverage emerging opportunities in speciality chemicals, supporting long-term growth and value creation.

BSCL – Building Future Capabilities

Driving import substitution through phased commissioning of high-value speciality chemical platforms

BSCL Unit II – Phase I Progress



STATUS: UNDER EXECUTION

- Greenfield project comprising HCN, Sodium Cyanide, EDTA & EDTA-2Na under execution.
- Commissioning targeted by end-FY27, creating a new speciality chemicals platform for pharmaceuticals, agrochemicals, mining and water treatment.

BSCL Unit I – EDA Derivatives Platform



STATUS: UNDER EXECUTION

- EDA derivatives project (DETA, TETA, PIP, AEEA & AEP) progressing as planned.
- Commissioning targeted during FY27, expanding the company's portfolio of high-value speciality amines.

Phase II Expansion



STATUS: PLANNED

- Tri Ethyl Ortho Formate (TEOF) identified as the next phase of expansion.
- Expands BSCL's value-added product portfolio and supports future commercialization.

CYANATION R&D PROCESS



IN-HOUSE R&D PROGRAMME

- Translating complex cyanide chemistry processes into commercial production to replace current import dependencies for domestic pharma and agrochemical sectors

BSCL is progressing through a phased expansion program that strengthens Company's speciality chemicals platform, enhances import substitution capabilities, and creates long-term growth opportunities across regulated and industrial markets.

Positioned for Sustainable Growth

Capex-to-Cashflow Inflection

- **₹1000 Cr+** expansion cycle nearing completion on consolidated basis
- FY27 Profit is expected to grow with a guidance at 200-300 bps.
- Earnings acceleration expected as **DME and ACN** are commercialized and **NMM** and BSCL projects ramp up in the ensuing FY

Unique Import-Substitution Franchise

- Only Indian producer of **Electronic Grade DMC** for EV battery applications
- India's first commercial-scale **DME (100 KTPA)** manufacturer
- The first and sole domestic manufacturer of **N-Methyl-2-Pyrrolidone (NMP)** in India
- Upcoming **HCN, Sodium Cyanide and EDTA** projects further strengthen import-replacement portfolio

Growth Without Leverage

- Standalone business remains **debt-free**
- Expansion funded through internal accruals
- Strong balance sheet with **₹2,262 Cr net worth** provides downside protection

Structural Margin Expansion

- Indigenous technology with **no royalty burden**
- Backward integration and methylamines scale-up driving cost leadership
- EBITDA margin targeted at **22-23% in FY27** vs ~20% in FY26

Balaji Amines is transitioning from an amines manufacturer to a speciality chemicals platform, driven by import substitution, EV-linked products, strong balance sheet strength and a large earnings-led capex payoff cycle.

BSCL – Scaling Speciality Chemicals

Balaji Speciality Chemicals

Product	Existing Licensed Capacity (TPA)	Proposed Capacity (TPA)	Total Capacity after Expansions (TPA)	Application Areas
Ethylenediamine	37,350	-	37,350	Pharma, Fungicides, Pesticides, Polymers and Coatings
Piperazine	4,050	3,300	7,350	Pharma, Oilfield
Diethylenetriamine	3,150	8,900	12,050	Coatings, Polymers, Pharma
Mixture of Amines (AEP, AEEA,HEP)	780	1,000	1,780	Multiple Industries
Mixture of TEPA & PEHA	-	1,000	1,000	Epoxy curing agents, Polyamide resins, Corrosion inhibitors, Adhesives and Sealants
Hydrogen Cyanide	-	10,000	10,000	Pharmaceuticals and agrochemicals, Mining chemicals
Sodium Cyanide (100% Pellet)	-	12,000	12,000	Gold and silver mining, Electroplating, Chemical intermediates
Triethylenetetramine (TETA)	-	3,000	3,000	Epoxy curing agents, Polyamide resins, Fuel additives, Corrosion inhibitors
Ammonium Sulphate	-	7,500	7,500	Fertilizers, Industrial applications, Chemical intermediates
Sodium Sulphate	-	5,300	5,300	Detergents and soaps, Glass manufacturing, Textile processing, Pulp and paper
Ethylene Diamine Tetra Acetic Acid (EDTA) & Ethylene Diamine Tetra Acetic Acid Disodium (EDTA-2Na)	-	5,000	5,000	Pharmaceuticals, Detergents and cleaning formulations
Total	**45,330**	**57,000**	**1,02,330**	

Manufacturing Capacity to Capture Future Demand

Balaji AMINES LIMITED ...A Speciality Chemical Company

Balaji Amines

Product	Existing Licensed Capacity (TPA)	Proposed Capacity (TPA)	Total Capacity after Expansions (TPA)	Application Areas
Methyl Amine	88,000	-	88,000	Pharma, Agro, Dye & Rubber
Ethyl Amine	22,500	-	22,500	Pharma, Agro, Dye & Rubber
DMAHCL / DMAC	31,000	7,500	38,500	Pharma
Choline Chloride 60% (Corn Cob)	6,000	-	6,000	Animal Feed
Choline Chloride 75% & 98%	6,000	-	6,000	Animal Feed
2P / NEP	33,000	-	33,000	Pharma, Agro, Petro, Dyes, Paints
NMP		-		Pharma, Agro, Petro, Dyes, Paints
GBL		-		Pharma, Agro, Petro, Dyes, Paints
DMU	3600	-	3600	Pharma, Textile, Agro
DMAE / DEAE	2,000	-	2,000	Cosmetics
Morpholine	10,000	-	10,000	Pharma, Agro, Dyes, Paints, Textile, Rubber
Other HCL'S	750	-	750	Animal Feed
DMF	30,000	-	30,000	Pharma, Agro, Polymers, Petro, Dyes, Paints
Acetonitrile (ACN)	18,000	-	18,000	Pharma, Petro, Textile, Plastics
PVP K-30	750	-	750	Pharma, Agro, Cosmetics
Di-methyl Carbonate (DMC)	15,000	-	15,000	Pharma, Polycarbonate, Automobiles
Propylene Glycol (PG)	15,000	-	15,000	Food Grade
Dimethyl Ether (DME)	1,00,000	-	1,00,000	Replacement of LPG
n-Butylamine	15,000	-	15,000	Pharma, Agro
N-Methyl Morpholine (NMM)	-	5,000	5,000	Pharma , Oil & Gas
MIPA/DIPA	6,000	-	6,000	Pharma, Agro, Dyestuff
Total	**4,02,600**	**12,500**	**4,15,100**	

A Diversified Product Portfolio

	Amines	Amine Derivatives	Speciality & Other Chemicals
Description	• The foundation of Balaji Amines' integrated value chain, supplying essential building blocks for a wide range of downstream chemicals. • The segment serves diverse industries through high-quality, vertically integrated manufacturing.	• Value-added products that expand the Company's presence across pharmaceutical, agrochemical and industrial applications. • This segment enhances product diversification while increasing value addition..	• A high-value portfolio serving advanced applications across pharmaceuticals, • EV batteries and speciality industries. Driven by indigenous technology and import substitution, the segment supports Balaji's future growth strategy.
Products	• Mono Methyl Amine (MMA) • Di Methyl Amine (DMA) • Tri Methyl Amine (TMA) • Mono Ethyl Amine (MEA) • Di Ethyl Amine (DEA) • Tri Ethyl Amine (TEA) • N-Butylamine, Isopropylamine • Dimethyl Amino Ethanol • Diethyl Amino Ethanol	• DMAC • DMA HCL • DMU • Corn Cob • Aqueous Solution	• Morpholine • Acetonitrile (ACN) • DME • DMF • NMP • GBL • DMC, Gamma-butyrolactone • Propylene Carbonate (PC) • Propylene Glycol (PG) • 2-Pyrrolidone, NEP, PVPK
Application	• Pharma • Agro • EV Battery • Photographic chemicals • Rocket fuel • Dyestuff intermediates • Rubber chemicals, etc	• Pharma • Pesticides • Performance chemicals • Speciality chemicals • Animal/poultry feed additive etc.	• Production of Water Treatment chemicals and pesticide formulations • Fuel Additives and EV Battery Chemicals • Solvents across industries like pharmaceuticals, petrochemicals, dyes, Agro and paint industries • Formulations and Intermediates in pharmaceuticals • Lubricant Manufacturing

Integrated Across the Value Chain

Balaji AMINES LIMITED ...A Speciality Chemical Company

Feedstock

Methanol

Ethanol

Ammonia, etc.

Core Amines

Methylamine

Ethylamine

Isopropylamine

N Butylamine

Amine Derivatives

DMAHCL

DMAC

DMU

Choline Chloride

Speciality Chemicals

Morpholine
DME, DMF
NMP, NEP , GBL
ACN
2P , PVPK
DMC , PC , PG
DMAE
DEAE

End Markets

Pharma

Agrochemicals EV

Batteries Industrial

Electronics Energy

Vertical Integration

Complete control from raw materials to speciality chemicals, enabling cost efficiency, quality consistency and supply reliability

90 - 95% of domestic demand met

For select key products, Balaji Amines' domestically developed processes. BAL demonstrating supply chain leadership at national scale, not just commercial scale

Diversified End Markets

Serving multiple high-growth industries including pharmaceuticals, agrochemicals, EV batteries, electronics and industrial chemicals

About Balaji Speciality Chemicals (BSCL)

Strategic Growth Platform

Balaji Speciality Chemicals Limited (BSCL), a 55% subsidiary of Balaji Amines Limited, is our strategic platform for high-value speciality chemicals. Located in Solapur, Maharashtra, BSCL commenced commercial operations in 2019 and is strengthening India's import substitution capabilities through speciality amines and derivatives. It obtained Mega project status by Government of Maharashtra.



Key Highlights

45,330 MTPA

Installed manufacturing capacity

Expanding Capacity – 57,000 MTPA

Addition of HCN, NACN and EDTA Plants

Import Substitution

Manufactures high-value speciality amines and derivatives

Global Presence

Exports to USA, Europe and other global markets

Why BSCL Matters

- Sole Indian manufacturer of key speciality amines and derivatives – **EDA, DETA, PIP, AEEA and AEP.**
- **REACH registrations*** for EDA, DETA and AEEA strengthen our access to regulated international markets.
- A key growth engine supporting Balaji Amines' **long-term growth strategy** and value creation.

REACH is a European Regulation and is an acronym for the Registration, Evaluation, Authorisation and Restriction of Chemicals.

Trusted by Industry Leaders Across the Globe

Balaji AMINES LIMITED ...A Speciality Chemical Company

Amines

Jubilant LifeSciences · Aurobindo (Committed to healthier life!) · Lupin · Piramal · Hetero · Rallis India Limited (A Tata Enterprise) · Coromandel (Future Positive) · Cipla · Dr. Reddy's · United Phosphorus Limited · Thermax · Amines Plasticizers

Amine Derivatives

Sun Pharma · Granules · Natco · Wanbury (Towards Better Healthcare) · Harman · USV · Wockhardt · Venky's · Aarti Drugs Ltd. · Kores (Where Value is Tradition) · Ipca (A dose of life)

Speciality & Other Chemicals

Hindustan Petroleum (HP) · IndianOil · CPCL · Bayer · Deepak (Responsible Chemistry) · Elantas · Teva tapi · Zydus (dedicated to life) · Hikal · Clariant · Cadila Pharmaceuticals Limited · Alembic (Touching Lives over 100 years) · GAIL · Mylan

Serving Diverse End Markets


















Industry Wise – Revenue Breakup



Expanding Global Footprints

Balaji AMINES LIMITED
...A Speciality Chemical Company

Country

UK
US
Argentina
Canada
Israel
India
Pakistan
Bangladesh
Oman
Germany
Italy
Egypt
South Africa
Korea
Taiwan
Spain
France
Belgium
Netherlands
Norway
Poland
Ukraine
Mexico
Brazil
Australia
China
Japan
Turkey
Finland
Indonesia
Switzerland
Sri Lanka
Russia
Malaysia
Singapore
Bahrain
Jordan
Guatemala
Colombia
Costa Rica
Thailand
Morocco
Peru
Venezuela
Philippines
Saudi Arabia
Vietnam
Ireland
Qatar
Kuwait
Denmark

OUR EXPORT PRESENCE

Delivering our products to
50+ countries across the world



Balaji AMINES LIMITED
...A Speciality Chemical Company

HOTEL
BALAJI SAROVAR



About Balaji Sarovar Premiere Hotel

- Commenced Operations in October 2013 Hotel Balaji Sarovar Premier is the only 5 star hotel in Solapur
- Invested Rs. 110 crore in the Hotel Project via mix of Debt and Equity
- Tied up with Sarovar Group for the Management of the Hotel on Management Fee + Revenue Share model
- Solapur is an important Tourist hub owing to its close proximity to Pandharphur, Tuljapur, Siddeshwar Temple, Ganagapur, Bijapur and Akkalkot
- Solapur attracts millions of Tourists and pilgrims every year



Hotel project has resulted in substantial cash flow savings

Balaji Sarovar Premiere – Q2 & H1 FY27 Operating Matrix

Renowned Five Star Hotel In the City of Solapur

BALAJI SAROVAR PREMIERE solapur
A SAROVAR HOTEL

129 Rooms	Constitutes **1.52%** of Total Revenue	Rs. **717 Lakhs** Revenue from Hotel Division
Rs. **4922** ADR	**67%** Occupancy Rate	Rs. **3288** RevPAR










ADR: Average Daily Rate
RevPAR: Revenue per Available Room


Balaji AMINES LIMITED
...A Speciality Chemical Company


HISTORICAL PERFORMANCE





Consolidated Performance Highlights














Strong Core ROCE Profile

Particulars (Rs. Crs.)	FY26	FY25
Consolidated Debt	133	11
Consolidated Networth	2152	2018
Total Capital Employed	**2285**	**2029**
Less: Investment in Hotel Balaji Sarovar & Others	95	117
Add: Loss in Hotel Balaji Sarovar & Others	35	43
Less: Investments in Capital Work in Progress in Greenfield project (Unit 4), Plant in Unit 3, Unit 1	187	173
Less: Investments by BSCL in Capital Work in Progress in Brownfield project (Unit 1) & Greenfield project (Unit 2)	343	116
Core Chemical Business Capital Employed (A)	**1695**	**1666**
EBIT on Consolidated Basis	238	217
Less: EBIT Loss Specific to Hotel Balaji Sarovar & Others	11	10
Core Chemical Business EBIT (B)	**227**	**207**
ROCE for Core Chemical Business (B/A)	**13%**	**12%**
ROCE at Consolidated Entity Level	**14%**	**11%**

Quarter and half year ended September 2026:


The capital work-in-progress across various units, totalling to Rs. 78.54 crore, pertains mainly to N-Methyl Morpholine (NMM) plant currently under development.

The capital work-in-progress at the subsidiary Balaji Speciality Chemicals Ltd (BSCL) amounts to Rs. 438.17 crore, and is allocated towards

1) A greenfield expansion to manufacture HCN, NaCN, EDTA, EDTA-Na, and other advanced chemical products
2) Brownfield expansions for EDA-based chemical production

Core chemical business continues to deliver a superior RoCE, reflecting the strong fundamentals and manufacturing capabilities that Balaji Amines has built over the years.

Consistent Dividend Payout



Particulars (Rs. per share)	FY21	FY22	FY23	FY24	FY25	FY26
Consolidated Book Value	281	406	524	584	623	664
Consolidated EPS	74	114	100	63	49	52
Dividend	4.00	6.00	10.00	11.00	11.00	11.00

Balaji AMINES LIMITED
...A Speciality Chemical Company

LEADERSHIP & RESPONSIBILITY



Highly Experienced Management Team



MR. A. PRATHAP REDDY

Executive Chairman

- Civil Engineer by Education. Incorporated BAL in 1988
- BAL's continuing success is a testimony to his entrepreneurial skills.
- His vision has made BAL today as one of the leading players in chemical industry.
- Honored with “Best CEO of emerging companies” in Chemical Sector.



MR. N. RAJESHWAR REDDY

Whole Time Director

- Commerce Graduate having over 48 years of experience across industries
- Instrumental in project commissioning with indigenous approach to improve return profile
- Responsible for operations in Solapur



MR. D. RAM REDDY

Managing Director

- 45 years of experience across various businesses.
- Focused on establishing customer and supplier's relationship with leading buyers and suppliers
- Responsible for the supply chain, sales and marketing
- Has been awarded the Lifetime Achievement Award from Punyashlok Ahilyadevi Holkar Solapur University in July` 24



MR. A. SRINIVAS REDDY


Whole Time Director & CFO

- Post Graduate in Computer Science and completed Executive Management Programme at ISB Hyderabad.
- More than 28 years experience in multiple Project Management Roles
- He is presently responsible for projects

Awards & Certificates – A Testimony of our capabilities



ISO Certificate



Three Star Export House



ISO Certificate



BEST CEO (CHEMICAL INDUSTRY) AWARD TO SHRI ANDE PRATHAP REDDY BY BUSINESS TODAY GROUP



ISO 9001 : 2015 Certificate



Certificate of Merit - CHEMEXCIL



First Award - CHEMEXCIL



WHO GMP Certificate

Awards & Recognition - A Testimony of our capabilities



Balaji Amines Limited has received the Best Project Award in the area of Healthcare, under the Large Enterprise category by Rotary India, National CSR Awards 2025



Balaji Amines Limited has been awarded as Sustainability Leader of the Year in Chemicals at FICCI Chemicals and Petrochemicals Awards 2025 by FICCI (Federation of Indian Chambers of Commerce and Industry



Balaji Sarovar Premiere, has been honoured with the Food Connoisseurs India Award for Restaurant Serving the best Chinese cuisine– 2026



Balaji Amines Limited has been conferred with the Narayan Meghaji Lokhande Occupational Safety & Health Award 2026 by the Directorate of Industrial Safety and Health (DISH), Government of Maharashtra.



On October 8, 2025, Balaji Amines Limited bagged the Western Zone Award in the Large-Scale Enterprise category for its outstanding work in the Healthcare Sector

ESG & CSR Initiatives



Constructed Classroom at ZPHS Chengal School, Mandal Bhimgal, Nizamabad, dt. 04.01.2025



Construction of Toilet Block at Indira Kale Prashala, Jalkotwadi, dt. 25.03.2025



Distributed Sanitary Napkin Incinerator and Vending Machine at Vishwabhushan Vidyalay, Solapur dt.30.09.2024



Distribution of Helmets for Highway Safety Squad Sambhaji Nagar dt. 17.02.2025



Distribution of SSC Board Exam Books in Solapur and Dharashiv dt. 15.01.2025



MPSC & UPSC competitive Examination Books and 1 Public System to Telugu Bhasha Abhivrudhhhi Sarvajanik Granthalayam, Solapur dt. 20.08.2024



Sponsorship to Sandhyarani Bandgar Tennis Player ITF Team Championship Turkey 09-03-2025

COMPANY :

Balaji Amines Limited

CIN-L24132MH1988PLC049387

Investor Relations Team

Email- cs@balajiamines.com

www.balajiamines.com

INVESTOR RELATIONS ADVISORS :

MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services

Mr. Nikunj Seth

nikunj.seth@in.mpms.mufg.com

Ms. Sakshi Mehta

sakshi.mehta@in.mpms.mufg.com

Meeting Request Link

THANK YOU

